Last update 16 Mar 2025
CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.

CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.

Subsidiary Company|
1997|
Hebei Sheng, China
|
www.e-cspc.com

Overview

Tags

Neoplasms
Other Diseases
Hemic and Lymphatic Diseases
Small molecule drug
Liposomal Drug
siRNA

Disease domain score
A glimpse into the focused therapeutic areas
Technology Platform
Most used technologies in drug development
Targets
Most frequently developed targets
Disease DomainCount
Nervous System Diseases2
Infectious Diseases2
Endocrinology and Metabolic Disease2
Hemic and Lymphatic Diseases1
Neoplasms1
Immune System Diseases1
Top 5 Drug TypeCount
Small molecule drug3
siRNA2
Chemical drugs1
Herbal medicine1
Liposomal Drug1
Top 5 TargetCount
PCSK9(Proprotein convertase subtilisin kexin type 9)1
NK1R(Neurokinin 1 receptor)1
L-type calcium channel(Voltage-gated L-type calcium channel)1
Top II(Topoisomerase II)1
AGT(Angiotensinogen)1

Related

7
Drugs associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
Mitoxantrone Hydrochloride liposomal
Target
Top II
Mechanism
Top II inhibitors
Active Org.
CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd.CSPC Zhongqi Pharmaceutical Technology Shijiazhuang Co., Ltd. [+5]
Originator Org.
CSPC Pharmaceutical Group Ltd.CSPC Pharmaceutical Group Ltd.
Active Indication
Peripheral T-Cell Lymphoma [+31]
Inactive Indication
Advanced gastric carcinoma [+16]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date01 Jun 2021
Shuxuening injection
Target-
Mechanism-
Active Org.
CSPC Yinhu Pharmaceutical Co., Ltd.CSPC Yinhu Pharmaceutical Co., Ltd.
Originator Org.
CSPC Yinhu Pharmaceutical Co., Ltd.CSPC Yinhu Pharmaceutical Co., Ltd.
Active Indication
Angina Pectoris [+2]
Inactive Indication-
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
China
First Approval Date16 Jul 2020
Clevidipine
Target
L-type calcium channel
Mechanism
L-type calcium channel blockers
Active Org.
Beijing Tide Pharmaceutical Co., Ltd.Beijing Tide Pharmaceutical Co., Ltd. [+5]
Originator Org.
The Medicines Company (Spain) SL
Active Indication
Hypertension [+2]
Inactive Indication
Acute decompensated heart failure [+5]
Drug Highest PhaseApproved
First Approval Ctry. / Loc.
United States
First Approval Date01 Aug 2008
43
Clinical Trials associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
NCT06842537
/ Not yet recruitingPhase 1
A Phase I Clinical Trial to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SYH2062 Injection in Healthy Chinese Volunteers
CTR20250311
/ RecruitingPhase 1
一项评价SYH2062注射液在中国健康受试者中的安全性、耐受性、药代动力学和药效学特征的Ⅰ期临床试验
[Translation] A Phase I clinical trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of SYH2062 injection in healthy Chinese subjects
NCT06770257
/ Not yet recruitingPhase 2IIT
A Randomized Phase ll Study Evaluating the Efficacy and Safety of Combination Therapy of Daunorubicin, Cytarabine Liposomes and Venetoclax Versus Combination Therapy of Azacitidine and Venetoclax in Newly Diagnosed AML Patients Not Eligible for Intensive Chemotherapy
100 Clinical Results associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
Login to view more data
0 Patents (Medical) associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
Login to view more data
100 Deals associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
Login to view more data
100 Translational Medicine associated with CSPC ZhongNuo Pharmaceutical (Shijiazhuang) Co. Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 20 Mar 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
IND Application
1
1
Phase 1
Phase 2
1
2
Phase 3
Approved
2
Login to view more data

Current Projects

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free